Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

被引：27

作者：

Fink, A. M. ^{[1
,2
,15
,16
]}

Bottcher, S. ^{[3
,15
,16
]}

Ritgen, M. ^{[3
]}

Fischer, K. ^{[1
,2
]}

Pflug, N. ^{[1
,2
]}

Eichhorst, B. ^{[1
,2
]}

Wendtner, C-M ^{[1
,2
]}

Winkler, D. ^{[4
]}

Buhler, A. ^{[4
]}

Zenz, T. ^{[4
,5
,6
,7
]}

Staib, P. ^{[8
]}

Mayer, J. ^{[9
,10
,11
]}

Hensel, M. ^{[5
,6
,7
]}

Hopfinger, G. ^{[12
]}

Wenger, M. ^{[13
]}

Fingerle-Rowson, G. ^{[1
,2
]}

Dohner, H. ^{[4
]}

Kneba, M. ^{[3
]}

Stilgenbauer, S. ^{[4
]}

Busch, R. ^{[14
]}

Hallek, M. ^{[1
,2
]}

机构：

[1] Dept Internal Med 1, Cologne, Germany

[2] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

[3] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany

[4] Klinikum Munchen Schwabing, Munich, Germany

[5] Univ Ulm, Dept Internal Med 3, Ulm, Germany

[6] Natl Ctr Tumor Dis NCT, Dept Translat Oncol, Heidelberg, Germany

[7] German Canc Res Ctr, Heidelberg, Germany

[8] Heidelberg Univ, Dept Med 5, Heidelberg, Germany

[9] St Antonius Hosp Eschweiler, Klin Hamatol & Onkol, Eschweiler, Germany

[10] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[11] Masaryk Univ, CEITEC, Brno, Czech Republic

[12] Mannheimer Onkol Praxis, Mannheim, Germany

[13] Hanusch Hosp Vienna, Dept Med 3, Vienna, Austria

[14] Paracelsus Med Univ, Dept Med 3, Salzburg, Austria

[15] F Hoffmann Roche Ltd, Pharmaceut Div, Basel, Switzerland

[16] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany

来源：

LEUKEMIA | 2013年 / 27卷 / 09期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; SURVIVAL; QUANTIFICATION; PROGRESSION;

D O I：

10.1038/leu.2013.190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1949 / +

页数：5

共 50 条

[1] Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
A M Fink
S Böttcher
M Ritgen
K Fischer
N Pflug
B Eichhorst
C-M Wendtner
D Winkler
A Bühler
T Zenz
P Staib
J Mayer
M Hensel
G Hopfinger
M Wenger
G Fingerle-Rowson
H Döhner
M Kneba
S Stilgenbauer
R Busch
M Hallek
Leukemia, 2013, 27 : 1949 - 1952
[2] FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE STUDY
Ionita, H.
Ionita, I.
Cheveresan, M.
Ionita, M.
Calamar, D.
Ionita, C. O.
Oros, D.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 526 - 526
[3] FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE ANALYSIS OF CZECH CLL STUDY GROUP
Smolej, L.
Lysak, D.
Papajik, T.
Salkova, J.
Brejcha, M.
Vozobulova, V.
Karban, J.
Hrudkova, M.
Cmunt, E.
Turcsanyi, P.
Jungova, A.
Krejcova, H.
Trneny, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 373 - 373
[4] Fludarabine, cyclophosphamide and rituximab (FCR) first-line therapy in CLL patients: an analysis of the registry of the German CLL Study Group
Fink, A. M.
Federhen, A.
Kutsch, N.
Stumpf, J.
Giza, A.
Robrecht, S.
Stoltefuss, A.
Vehling-Kaiser, U.
Koenigsmann, M.
Tausch, E.
Schneider, C.
Stilgenbauer, S.
Illmer, T.
Schlag, R.
Doerfel, S.
Gaska, T.
Kiehl, M.
Fischer, K.
Eichhorst, B.
Hallek, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 119 - 120
[5] Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma
De la Cruz Vicente, Fatima
Carrillo-Cruz, Estrella
Sole Rodriguez, Maria
Marin Niebla, Ana
Martino Galiana, Maria Luz
Falantes Gonzalez, Jose
Montero Cuadrado, Isabel
Gonzalez Campos, Jose
Espigado Tocino, Ildefonso
Rios-Herranz, Eduardo
Antonio Perez-Simon, Jose
EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (06) : 469 - 475
[6] Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)
Fink, Anna
Busch, Raymonde
Pflug, Natali
Boettcher, Sebastian
Winkler, Dirk
Buehler, Andreas
Ritgen, Matthias
Fischer, Kirsten
Eichhorst, Barbara
Wendtner, Clemens-Martin
Mendila, Myriam
Wenger, Michael K.
Doehner, Hartmut
Kneba, Michael
Stilgenbauer, Stephan
Hallek, Michael
BLOOD, 2011, 118 (21) : 446 - 447
[7] Outcome of First Salvage Therapy in Patients With Chronic Lymphocytic Leukemia Relapsing After First-line Fludarabine, Cyclophosphamide, and Rituximab
Badoux, Xavier
Tam, Constantine
Lerner, Susan
Wierda, William
Keating, Michael J.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (06): : E39 - E40
[8] Fludarabine, cyclophosphamide and rituximab (FCR) in front line treatment of patients with chronic lymphocytic leukemia (CLL)
Grifi, Fatiha
Bougherira, Soraya
Djenouni, Amel
LEUKEMIA & LYMPHOMA, 2017, 58 : 94 - 94
[9] Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma
Vicente, Fatima de la Cruz
Cruz, Estrella Carrillo
Rodriguez, Maria Sole
Niebla, Ana Marin
Herranz, Eduardo Rios
Galiana, Maria Luz Martino
Gonzalez, Jose Falantes
Cuadrado, Isabel Montero
Campos, Jose Gonzalez
Tocino, Ildefonso Espigado
Perez-Simon, Jose A.
BLOOD, 2013, 122 (21)
[10] Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM)
Bosch, Francesc
Villamor, Neus
Abrisqueta, Pau
Jose Terol, Maria
Gonzalez-Barca, Eva
Gonzalez, Marcos
Ferra, Christelle
Abella, Eugenia
Delgado, Julio
Garcia-Marco, Jose A.
Gonzalez, Yolanda
Carbonell, Felix
Ferrer, Secundino
Monzo, Encarna
Jarque, Isidro
Muntanola, Ana
Constants, Mireia
Escoda, Lourdes
Montserrat, Emili
BLOOD, 2010, 116 (21) : 594 - 595

← 1 2 3 4 5 →